lactiplantibacillus plantarum LLY-606

**Lactiplantibacillus plantarum LLY-606** is a specific strain of *Lactiplantibacillus plantarum*, a probiotic bacterium originally known as *Lactobacillus plantarum*. This strain exhibits therapeutic properties via modulation of gut microbiota and has shown potential benefits in several areas: - **Mechanism of Action**: LLY-606 exerts its effects primarily by colonizing the gut, restoring or maintaining intestinal homeostasis, regulating inflammation (notably via downregulation of the TLR4/MyD88/NF-κB signaling pathway), improving antioxidant capacity, and influencing host metabolism. In models of hyperuricemia, LLY-606 reduces serum uric acid levels by inhibiting uric acid secretion and modulating uric acid transport. In obesity, it enhances arginine production and activates the AMPK pathway, leading to improved lipid metabolism. In aging models, it ameliorates cognitive impairment and prolongs lifespan through regulation of gut microbiota, improved synaptic plasticity, and increased neurotrophic factors[1][2][3]. - **Primary Indications**: Research studies and synbiotic formulations including LLY-606 have primarily targeted metabolic disorders (hyperuricemia, obesity), cognitive aging, and gut health. Human and animal studies suggest benefits in obesity-related lipid metabolism and aging-related cognitive decline[2][3][1]. - **Developer**: Key research and development has been performed by Northwest A&F University and BGI Institute of Applied Agriculture[1][3].

Other names

lactobacillus plantarum LLY-606